Key Highlights

  • Toscafund's deadline to announce a firm 250p-a-share offer was extended a third time, to 3 September 2026.
  • Interim results for the six months to 30 June 2026 were pushed from 9 September to 30 September.
  • FY2025 Revenue rose 4.5% to £1,579.8m, but profit before tax fell 51.4% to £18.6m.
  • Adjusted free Cash Flow jumped 64.9% to £64.3m as Capital spending fell to £78.5m.

Spire Healthcare Group PLC (LSE:SPI) reaches a decisive moment this week. By 5.00pm on Thursday 3 September 2026, Toscafund Asset Management, the private hospital operator's second-largest shareholder, must either table a firm offer at its proposed 250 pence per share or walk away under the Takeover Code's "put up or shut up" rules. The deadline has already been extended three times since the approach was disclosed on 14 May.

With the shares trading at around 235p, below the proposal, and interim results pushed back to 30 September, the coming weeks will decide whether a year-long strategic review ends in an agreed takeover or a return to standalone life.

Toscafund's 250p proposal: deadline extended to 3 September

On 21 August 2026 Spire said it had agreed, with Takeover Panel consent, to extend Toscafund's deadline to announce a firm intention to make an offer from 21 August to 3 September. Toscafund's "due diligence has concluded" and it needed time "to finalise its financing arrangements, which are near-final". The same day, Spire moved its interim results for the six months to 30 June 2026 from 9 September to 30 September, without giving a reason.

The possible offer was disclosed on 14 May 2026: 250p in cash per share, with an option to elect an unlisted rollover alternative. The board said it was minded to support such an offer unanimously should a firm offer be made on those terms, having rejected "a number of earlier proposals" from Toscafund. Toscafund is reported to hold an 18% stake, with the proposal valuing Spire at roughly £1bn.

Spire entered an Offer Period on 18 September 2025 when it launched a strategic review covering a potential sale, value from its hospital properties and operational changes. In January 2026 it named Private Equity groups Bridgepoint and Triton as parties in talks; both walked away on 20 March, Bridgepoint citing an inability to find "a transaction structure that would work for all Stakeholders at this time". That leaves Toscafund as the sole suitor, and the board cautions that "there can be no certainty that any firm offer will be made".

Business overview: private hospitals with three payor groups

Spire Healthcare is a leading independent healthcare provider in the UK. At its March 2026 results it operated 38 hospitals and more than 60 clinics, medical centres and consulting rooms across England, Wales and Scotland, delivering diagnostics, surgery and outpatient care.

Revenue comes from three payor groups: privately insured patients (PMI), self-pay patients and the NHS, which buys independent-sector capacity to cut waiting lists. In FY2025, hospital revenue of £1,446.1m comprised £1,010.1m from private patients (£681.5m PMI, £328.6m self-pay) and £407.9m from the NHS. A smaller Primary Care segment, built around Vita Health Group, provides NHS Talking Therapies and mental-health services and generated £133.7m. Spire is listed on the London Stock Exchange's Main Market.

FY2025 results: revenue up 4.5%, cash flow up sharply, statutory profit halved

Preliminary results for the year to 31 December 2025, published on 5 March 2026, showed revenue of £1,579.8m, up 4.5%. NHS revenue grew 11.4%, though growth slowed to 6.8% in the second half as commissioners introduced Activity Management Plans; PMI rose 2.9% and self-pay slipped 1.3%.

Adjusted EBITDA rose 3.2% to £268.6m, a 17.0% margin. Below that line it was tougher: reported operating profit fell 10.8% to £122.6m and profit before tax dropped 51.4% to £18.6m, with basic EPS down 34.9% to 4.1p. Adjusted profit before tax was £46.5m (down 7.4%), while adjusted EPS rose 9.6% to 9.6p.

Cash generation was the highlight. Adjusted free cash flow jumped 64.9% to £64.3m as Capital Expenditure fell to £78.5m from £112.1m. Net bank Debt ended the year at £332.4m (£325.9m a year earlier), with Lease liabilities of £948.7m; Leverage was unchanged at 2.0 times. The cost programme delivered £30m of new savings in 2025, £80m cumulatively since FY22, partly by removing around 400 permanent clinical roles. The final Dividend was cut to 1.5p from 2.3p.

Chief executive Justin Ash called it "a resilient performance against a backdrop of increased costs and changes in the NHS commissioning environment towards the end of the year." For 2026, Spire guided to adjusted EBITDA "broadly in line with FY25", warning that first-quarter NHS revenue would fall by roughly 25% year on year, offset by a further £30m of targeted savings. The 14 May trading update to April said private revenue "continued to grow strongly, particularly self-pay", more than 85% of NHS commissioning for the rest of the year was agreed, and the EBITDA target was reaffirmed.

What could drive the stock next?

The binary catalyst is Thursday's PUSU deadline. A firm Rule 2.7 offer at 250p would start a scheme timetable; a further extension or a Withdrawal would send the shares back to trading on fundamentals. Toscafund retains the right to reduce its terms in certain circumstances, so the precise terms of any firm offer will be scrutinised.

Beyond the bid, interim results on 30 September will show whether the first-quarter NHS hit has been absorbed and the FY26 EBITDA target still holds. Progress on the £30m savings target, self-pay momentum and any move to extract value from the property estate are the other levers, alongside board succession after reports in July that chair Ian Cheshire is to step down.

Risks investors should watch

The most immediate risk is deal failure. Two private equity bidders have already left, and Toscafund's financing was still being finalised at the last update. If the offer lapses, the shares could lose the bid support they have enjoyed since May; if it proceeds, shareholders must weigh cash against an illiquid, unlisted rollover instrument.

Operationally, NHS commissioning is the dominant uncertainty. Spire does not expect NHS revenue growth in 2026 and says the 2026/27 Tariff uplift is around zero, while costs keep rising; NHS work was over a quarter of hospital revenue in 2025. Reported profit before tax has already halved, and £332.4m of net bank debt plus almost £950m of lease liabilities limit flexibility if EBITDA slips. Self-pay Demand is sensitive to household finances, and a cost programme built on workforce change carries execution and clinical-quality risk in a heavily regulated sector.

Outlook

Spire (LSE:SPI) enters September with a clear test. The board would support a 250p cash offer, Due Diligence is complete and financing is "near-final", yet three extensions and a share price below the proposal show nothing is settled until a firm offer is announced. Watch the 3 September statement, then the delayed interims on 30 September for evidence that private-patient growth and savings are offsetting a shrinking NHS contribution. Whether or not Toscafund proceeds, adjusted EBITDA "broadly in line with FY25" is the benchmark for the standalone business.